ReviewPharmaceutical research2008
Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.
Review in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- Antitumor Properties of Matrikines of Different Origins: Prospects and Problems of Their Application.International journal of molecular sciences · 2023Review
- Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptideDrug delivery · 2021Article
- Retraction Note: Inhibition of Tumor Angiogenesis by Tumstatin: Insights into Signaling Mechanisms and Implications in Cancer Regression.Pharmaceutical research · 2021Article
- Bioactive fragments of laminin and collagen chains: lesson from the testis.Reproduction (Cambridge, England) · 2020Review
- Cdc42 is involved in NC1 peptide-regulated BTB dynamics through actin and microtubule cytoskeletal reorganization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Antitumor mechanisms of bifidobacteria.Oncology letters · 2018Review
- Regulation of spermatogenesis by a local functional axis in the testis: role of the basement membrane-derived noncollagenous 1 domain peptide.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Vector-mediated Tum-5 expression in neovascular endothelial cells for treating hepatocellular carcinoma.Experimental and therapeutic medicine · 2017Article
- Collagen type IV at the fetal-maternal interface.Placenta · 2015Article
- Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.Scientific reports · 2014Article
- NC1 domain of collagen α3(IV) derived from the basement membrane regulates Sertoli cell blood-testis barrier dynamics.Spermatogenesis · 2013Article
- Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosis.PloS one · 2013Article
- Article
- L-arginine mediated renaturation enhances yield of human, α6 Type IV collagen non-collagenous domain from bacterial inclusion bodies.Protein and peptide letters · 2012Article
- Review
- Basement membrane components are key players in specialized extracellular matrices.Cellular and molecular life sciences : CMLS · 2010Review
- Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo Activities.Journal of cancer science & therapy · 2010Article
- Novel aspects of corneal angiogenic and lymphangiogenic privilege.Progress in retinal and eye research · 2010Review
- History of Cancer, Ancient and Modern Treatment Methods.Journal of cancer science & therapy · 2009Article
- Integrins as "functional hubs" in the regulation of pathological angiogenesis.Seminars in cancer biology · 2009Review
Corrections and comments
- Expression of concern · 2020-06-05Concerns/Issues about Image · Investigation by ORI · Updated to Retraction · · Yakkanti Sudhakar has aka of Yakkanti Akul Sudhakar, Akulapalli Sudhakar, and Sudhakar Yakkanti; Sudhakar Yakkanti has ORI finding of misconduct; https://ori.hhs.gov/content/case-summary-yakkanti-sudhakar;
- Retraction · 2021-01-15Duplication of/in Image · Investigation by Company/Institution · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) · · Yakkanti Sudhakar has aka of Yakkanti Akul Sudhakar, Akulapalli Sudhakar, and Sudhakar Yakkanti; Sudhakar Yakkanti has ORI finding of misconduct; https://ori.hhs.gov/content/case-summary-yakkanti-sudhakar;
- Commented on by
- Retracted
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing tumors develop additional new blood vessels to meet the demand for adequate nutrients and oxygen, a process called angiogenesis. Cancer is a highly complex disease promoted by excess angiogenesis; interfering with this process poses for an attractive approach for controlling tumor growth. This hypothesis led to the identification of endogenous angiogenesis inhibitors generated from type IV collagen, a major component of vascular basement membrane (VBM). Type IV collagen and the angiogenesis inhibitors derived from it are involved in complex roles, than just the molecular construction of basement membranes. Protease degradation of collagens in VBM occurs in various physiological and pathological conditions and produces several peptides. Some of these peptides are occupied in the regulation of functions conflicting from those of their original integral molecules. Tumstatin (alpha3(IV)NC1), a proteolytic C-terminal non-collagenous (NC1) domain from type IV collagen alpha3 chain has been highlighted recently because of its potential role in anti-angiogenesis, however its biological actions are not limited to these processes. alpha3(IV)NC1 inhibits proliferation by promoting endothelial cell apoptosis and suppresses diverse tumor angiogenesis, thus making it a potential candidate for future cancer therapy. The present review surveys the physiological functions of type IV collagen and discovery of alpha3(IV)NC1 as an antiangiogenic protein with a comprehensive overview of the knowledge gained by us towards understanding its signaling mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.